title: Alzheimer's disease--subcortical vascular disease spectrum in a hospital-based setting: Overview of results from the Gothenburg MCI and dementia studies.
abstract: The ability to discriminate between Alzheimer's disease (AD), subcortical vascular disease, and other cognitive disorders is crucial for diagnostic purposes and clinical trial outcomes. Patients with primarily subcortical vascular disease are unlikely to benefit from treatments targeting the AD pathogenic mechanisms and vice versa. The Gothenburg mild cognitive impairment (MCI) and dementia studies are prospective, observational, single-center cohort studies suitable for both cross-sectional and longitudinal analysis that outline the cognitive profiles and biomarker characteristics of patients with AD, subcortical vascular disease, and other cognitive disorders. The studies, the first of which started in 1987, comprise inpatients with manifest dementia and patients seeking care for cognitive disorders at an outpatient memory clinic. This article gives an overview of the major published papers (neuropsychological, imaging/physiology, and neurochemical) of the studies including the ongoing Gothenburg MCI study. The main findings suggest that subcortical vascular disease with or without dementia exhibit a characteristic neuropsychological pattern of mental slowness and executive dysfunction and neurochemical deviations typical of white matter changes and disturbed blood-brain barrier function. Our findings may contribute to better healthcare for this underrecognized group of patients. The Gothenburg MCI study has also published papers on multimodal prediction of dementia, and cognitive reserve.
authors.forename: Anders
authors.initials: A
authors.lastname: Wallin
authors.forename: Arto
authors.initials: A
authors.lastname: Nordlund
authors.forename: Michael
authors.initials: M
authors.lastname: Jonsson
authors.forename: Kaj
authors.initials: K
authors.lastname: Blennow
authors.forename: Henrik
authors.initials: H
authors.lastname: Zetterberg
authors.forename: Annika
authors.initials: A
authors.lastname: Öhrfelt
authors.forename: Jacob
authors.initials: J
authors.lastname: Stålhammar
authors.forename: Marie
authors.initials: M
authors.lastname: Eckerström
authors.forename: Mårten
authors.initials: M
authors.lastname: Carlsson
authors.forename: Erik
authors.initials: E
authors.lastname: Olsson
authors.forename: Mattias
authors.initials: M
authors.lastname: Göthlin
authors.forename: Johan
authors.initials: J
authors.lastname: Svensson
authors.forename: Sindre
authors.initials: S
authors.lastname: Rolstad
authors.forename: Carl
authors.initials: C
authors.lastname: Eckerström
authors.forename: Maria
authors.initials: M
authors.lastname: Bjerke
mesh_terms: D000544:Alzheimer Disease / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D015415:Biomarkers / Q000097:blood; D000068456:Clinical Studies as Topic / Q000379:methods*; D002986:Clinical Trials as Topic / Q000379:methods; D015140:Dementia, Vascular / Q000097:blood / Q000175:diagnosis* / Q000473:pathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D064887:Observational Studies as Topic / Q000379:methods; D012107:Research Design
chemical_list: D015415:Biomarkers